Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 114,805,000	$ 139,065,000
Short-term marketable securities (amortized cost of $250,448 and $214,115, respectively)	248,757,000	213,996,000
Accounts receivable, net	22,518,000	17,409,000
Inventory	21,002,000	19,263,000
Prepaid expenses and other current assets	12,038,000	13,015,000
Total current assets	419,120,000	402,748,000
Long-term assets
Property and equipment, net	85,994,000	85,262,000
Operating lease right-of-use assets	85,634,000	87,678,000
Long-term marketable securities (amortized cost of $140,202 and $218,163, respectively)	137,110,000	217,145,000
Restricted cash	2,382,000	2,138,000
Intangible assets, net	8,107,000	8,526,000
Goodwill	118,972,000	118,972,000
Other assets	874,000	875,000
Total assets	858,193,000	923,344,000
Current liabilities
Accounts payable	5,959,000	3,307,000
Accrued liabilities	10,407,000	9,343,000
Accrued compensation and benefits	6,651,000	15,642,000
Current portion of operating lease liabilities	8,545,000	5,055,000
Current portion of deferred revenue	83,504,000	80,460,000
Total current liabilities	115,066,000	113,807,000
Long-term liabilities
Operating lease liabilities, less current portion	104,978,000	106,685,000
Deferred revenue, less current portion	84,894,000	98,750,000
Total liabilities	304,938,000	319,242,000
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2022 and December 31, 2021; 142,183,258 and 141,393,865 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	14,000	14,000
Additional paid-in capital	1,339,601,000	1,324,006,000
Accumulated other comprehensive loss	(4,783,000)	(1,137,000)
Accumulated deficit	(781,627,000)	(718,891,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity	553,205,000	603,992,000
Noncontrolling interest	50,000	110,000
Total shareholders’ equity	553,255,000	604,102,000
Total liabilities and shareholders’ equity	$ 858,193,000	$ 923,344,000